Plasma amyloid‐β oligomerization tendency predicts amyloid PET positivity

Background Among other emerging amyloid-targeting blood-based biomarkers, Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) measures dynamic changes in concentration of oligomeric amyloid-β (OAβ), which is considered the main pathogenic culprit Alzheimer’s disease (AD), plasma after spiking with synthetic (Aβ). We aimed to investigate predictability MDS-OAβ on amyloid Positron Emission Tomography (PET) positivity. Method A total 96 subjects who visited Seoul National University Bundang Hospital for medical check-up complaining cognitive decline and had undergone extensive assessment were recruited. Amyloid statuses dichotomized into positive or negative based visual PET. Plasma OAβ was measured by MDS-OAβ. In previous validation study, 0.78ng/ml established as cut-off value higher than equal defined positive. Result positivity could discriminate PET AUC 0.855 (95% CI 0.776–0.933). Adding prediction models including age, MMSE score, APOE ε4 status improved performance up 0.926 0.871–0.980). Conclusion The Aβ oligomerization tendency predict high performance, when it combined status, substantially. This suggests potential a useful initial stage test clinical research field AD.